SAMSRITA LABS LIMITED (SAMSRITA.BO)
INR 24.14
(0.0%)
INR 24.14
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.46 Million INR | 74.91% |
| 2022 | -7 Million INR | -147.3% |
| 2021 | -4.02 Million INR | 55.96% |
| 2020 | -7.57 Million INR | 58.44% |
| 2019 | -21.86 Million INR | 10.76% |
| 2018 | -24.46 Million INR | -117.07% |
| 2017 | -11.27 Million INR | -92.54% |
| 2016 | -5.84 Million INR | -1316.59% |
| 2015 | - INR | -49.29% |
| 2014 | - INR | 13.93% |
| 2013 | - INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -865 Thousand INR | -25.0% |
| 2023 Q4 | -692 Thousand INR | -53.78% |
| 2023 Q1 | -856 Thousand INR | 89.31% |
| 2023 Q2 | -480 Thousand INR | 43.93% |
| 2023 Q3 | -450 Thousand INR | 6.25% |
| 2023 FY | - INR | 75.05% |
| 2022 Q1 | -875 Thousand INR | 57.19% |
| 2022 Q4 | -8 Million INR | -1368.81% |
| 2022 Q2 | -441 Thousand INR | 49.6% |
| 2022 FY | - INR | -147.3% |
| 2022 Q3 | -545 Thousand INR | -23.58% |
| 2021 Q1 | -823 Thousand INR | 0.0% |
| 2021 FY | - INR | 55.96% |
| 2021 Q4 | -2.04 Million INR | -257.97% |
| 2021 Q3 | -571 Thousand INR | 9.37% |
| 2021 Q2 | -630 Thousand INR | 23.45% |
| 2020 FY | - INR | 58.44% |
| 2019 FY | - INR | 10.76% |
| 2018 FY | - INR | -117.07% |
| 2017 FY | - INR | -92.54% |
| 2016 FY | - INR | -1316.59% |
| 2015 FY | - INR | -49.29% |
| 2014 FY | - INR | 13.93% |
| 2013 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alfavision Overseas (India) Limited | 10.12 Million INR | 124.303% |
| Biocon Limited | 41.52 Billion INR | 100.006% |
| Blue Jet Healthcare Limited | 2.29 Billion INR | 100.107% |
| Concord Biotech Limited | 4.65 Billion INR | 100.053% |
| Dishman Carbogen Amcis Limited | 3.07 Billion INR | 100.08% |
| FERMENTA BIOTECH LIMITED | 262.68 Million INR | 100.937% |
| GENOMIC VALLEY BIOTECH LIMITED | 147.4 Thousand INR | 1769.211% |
| Lyka Labs Limited | 167.58 Million INR | 101.468% |
| Panacea Biotec Limited | -200.6 Million INR | 98.773% |
| Servoteach Industries Limited | - INR | Infinity% |
| SMS Lifesciences India Limited | 349.41 Million INR | 100.704% |
| Supriya Lifescience Limited | 1.83 Billion INR | 100.134% |
| Syngene International Limited | 10.84 Billion INR | 100.023% |
| TAKE Solutions Limited | -1.05 Billion INR | 99.766% |
| Titan Biotech Limited | 360.29 Million INR | 100.683% |
| Transgene Biotek Limited | -4.33 Million INR | 43.295% |
| Vanta Bioscience Limited | 14.19 Million INR | 117.338% |